Biogen acquires sole rights to MS drug from Elan for $3.25B

02/7/2013 | Reuters · Genetic Engineering & Biotechnology News

Biogen Idec agreed to pay Elan $3.25 billion plus future royalties to acquire all rights to multiple sclerosis drug Tysabri, or natalizumab. Tysabri was jointly developed by Biogen and Elan. The deal will strengthen Biogen's presence in the multiple sclerosis drug market as it awaits the FDA's decision on another MS drug, Tecfidera, or dimethyl fumarate.

View Full Article in:

Reuters · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA
Group Health Cooperative
Group Health Cooperative
Seattle, WA
Systems Test - V&V Engineer - 14000008LS
Abbott
San Jose, CA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)